ArticleJournal of inflammation research2026
The Systemic Immune-Inflammation Index as a Predictor of Clinical Outcomes in Chronic Coronary Syndrome: Influence of Diabetes Mellitus.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation plays a critical role in the prognosis of coronary heart disease, and the Systemic Immune-Inflammation Index (SII) reflects both inflammatory status and immune balance. While elevated SII has been associated with adverse outcomes, its prognostic value in chronic coronary syndrome (CCS), particularly among diabetic patients, remains unclear. Hyperglycemia-induced inflammation, which enhances neutrophil activation and platelet reactivity, contributes to a more severe atherosclerosis burden in diabetes. This study investigated the predictive value of SII in CCS patients and examined whether diabetes modifies this relationship. Methods: From January to December 2022, a cohort of 853 individuals with CCS who underwent coronary angiography was retrospectively analyzed and stratified by SII and glycometabolic status. This retrospective cohort study utilized fully anonymized data from the Coronary Heart Disease Database of Nanjing Drum Tower Hospital. Major adverse cardiovascular and cerebrovascular events (MACCEs), comprising cardiovascular death, nonfatal myocardial infarction, heart failure, ischemia-driven revascularization, and stroke, served as the primary endpoints. Kaplan-Meier analysis, Cox proportional hazard models, and restricted cubic spline (RCS) models were performed to evaluate the independent and combined effects of SII and glycometabolic status on clinical outcomes. Results: Over a median follow-up period of 36 months, 85 patients (9.96%) experienced MACCEs. Higher log-transformed SII remained an independent predictor of MACCEs in the whole cohort (hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.05-2.55, Conclusion: Elevated SII levels independently predict adverse outcomes in patients with CCS, with a stronger prognostic effect among those with diabetes. These findings suggest that SII may serve as a simple and accessible marker for personalized risk stratification in CCS, especially in patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.